Asthma: New Discoveries and Therapies in the Age of COVID

Organizer(s): Michael J. Holtzman, Philippa C. Marrack, Anne I. Sperling and Prescott G. Woodruff

Sponsored by Ionis Pharmaceuticals, Inc.

For important information on the coronavirus, please click here

Summary of Meeting:

Asthma and related diseases in the form of COPD and asthma-COPD are a remarkably common, affecting over 50 million patients in the US alone. Moreover, this disease spectrum overlaps with inflammatory lung disease driven by respiratory viral infection, including COVID-19. In the case of asthma, the pathology is thought to arise from an aberrant type 2 immune response, but the cellular and molecular mechanisms of this response require more precise definition, including any contribution from non-type 2 immune mechanisms. Clinical trials based on these concepts have revealed both successes and also some unforeseen failures that need to be addressed and included in the framework of respiratory viruses in general and SARS-CoV-2 in particular. This Keystone Symposia conference on asthma will highlight the most recent basic science breakthroughs in the pathogenesis of asthma and related inflammatory airway diseases and focus on the development of new therapeutics for asthma and related progressive respiratory disease. In addition, the program will review these discoveries in the context of new therapeutic directions, including the context of emerging information about COVID-19. The program has been designed to emphasize to identify, validate, and translate new disease targets into new therapeutics. The topic is timely and urgent given the recent mechanistic insights into inflammatory airway disease, the current maturation of new biological therapies for this type of disease, and the overlap of this information with progressive lung disease after respiratory viral infections, including COVID-19.

Global Health Travel Award Deadline: November 17 2020

Scholarship Deadline: October 17 2020

Abstract Deadline: November 3 2020

Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:

We gratefully acknowledge the generous grant for this conference provided by:

National Heart, Lung, and Blood Institute (NHLBI)
Grant No. 1 R13 HL152474-01
Funding for this conference was made possible (in part) by 1 R13 HL152474-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations